CL2023000037A1 - Therapeutic RNA for HPV-positive cancer - Google Patents
Therapeutic RNA for HPV-positive cancerInfo
- Publication number
- CL2023000037A1 CL2023000037A1 CL2023000037A CL2023000037A CL2023000037A1 CL 2023000037 A1 CL2023000037 A1 CL 2023000037A1 CL 2023000037 A CL2023000037 A CL 2023000037A CL 2023000037 A CL2023000037 A CL 2023000037A CL 2023000037 A1 CL2023000037 A1 CL 2023000037A1
- Authority
- CL
- Chile
- Prior art keywords
- hpv
- cancer
- positive cancer
- positive
- therapeutic rna
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 8
- 201000011510 cancer Diseases 0.000 title abstract 5
- 230000001225 therapeutic effect Effects 0.000 title abstract 3
- 208000022361 Human papillomavirus infectious disease Diseases 0.000 abstract 3
- 208000000102 Squamous Cell Carcinoma of Head and Neck Diseases 0.000 abstract 2
- 201000000459 head and neck squamous cell carcinoma Diseases 0.000 abstract 2
- 102000040650 (ribonucleotides)n+m Human genes 0.000 abstract 1
- 206010008342 Cervix carcinoma Diseases 0.000 abstract 1
- 206010061818 Disease progression Diseases 0.000 abstract 1
- 206010027476 Metastases Diseases 0.000 abstract 1
- 208000002471 Penile Neoplasms Diseases 0.000 abstract 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 abstract 1
- 201000010881 cervical cancer Diseases 0.000 abstract 1
- 230000005750 disease progression Effects 0.000 abstract 1
- 210000004392 genitalia Anatomy 0.000 abstract 1
- 230000009401 metastasis Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000004083 survival effect Effects 0.000 abstract 1
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Esta invención se relaciona con el campo del ARN terapéutico para tratar el cáncer positivo para VPH, en particular, los cánceres anogenitales, cervicales y de pene y el cáncer en la región de la cabeza y el cuello, tal como el cáncer en la región genital y el carcinoma de células escamosas de cabeza y cuello (HNSCC). En el presente documento se describen composiciones, usos y métodos para el tratamiento de cánceres positivos para VPH. La administración de ARN terapéuticos a un paciente que tiene cáncer VPH positivo descrito en este documento puede reducir el tamaño del tumor, prolongar el tiempo hasta la progresión de la enfermedad y/o proteger contra la metástasis y/o la recurrencia del tumor y, en última instancia, prolongar el tiempo de supervivencia.This invention relates to the field of therapeutic RNA for treating HPV positive cancer, in particular, anogenital, cervical and penile cancers and cancer in the head and neck region, such as cancer in the genital region. and head and neck squamous cell carcinoma (HNSCC). Described herein are compositions, uses and methods for the treatment of HPV-positive cancers. Administration of therapeutic RNAs to a patient who has HPV-positive cancer described herein may reduce tumor size, prolong time to disease progression, and/or protect against tumor metastasis and/or recurrence and, in ultimately prolong survival time.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP20069146 | 2020-07-07 |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2023000037A1 true CL2023000037A1 (en) | 2023-10-13 |
Family
ID=88840011
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2023000037A CL2023000037A1 (en) | 2020-07-07 | 2023-01-05 | Therapeutic RNA for HPV-positive cancer |
Country Status (1)
Country | Link |
---|---|
CL (1) | CL2023000037A1 (en) |
-
2023
- 2023-01-05 CL CL2023000037A patent/CL2023000037A1/en unknown
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2019001920A (en) | Rna for cancer therapy. | |
CL2020000501A1 (en) | Ectonucleotide pyrophosphatase-phosphodiesterase 1 (enpp1) inhibitors and their uses. | |
MX2020009773A (en) | Combination therapy. | |
EA201790404A1 (en) | MACROPINOCYTOZING HUMAN ANTI-CD46 ANTIBODIES AND TARGET TREATMENT OF CANCER | |
MX2019010202A (en) | Glycan-interacting compounds and methods of use. | |
MY189713A (en) | Duocarmycin adcs for use in treatment of endometrial cancer | |
MX2019003134A (en) | Combination therapy. | |
MX2020001727A (en) | Combination therapy. | |
AR110730A1 (en) | LISTERY AND METHOD RECOMBINANT VACCINE VACCINES FOR USE IN CANCER IMMUNOTHERAPY | |
MX2019013862A (en) | Combination therapy. | |
ECSP21006416A (en) | FORMULATIONS OF AN AXL / MER INHIBITOR | |
CL2020000508A1 (en) | Anti-egfr drug-antibody (adc) conjugates and their uses. | |
CL2020000270A1 (en) | Therapeutic combination of a third generation egfr tyrosine kinase inhibitor and a raf inhibitor. | |
MX2020013601A (en) | Cancer-specific t-cell receptors. | |
MX2018010223A (en) | Combination therapy for treatment of ovarian cancer. | |
CL2023000037A1 (en) | Therapeutic RNA for HPV-positive cancer | |
CO2023001133A2 (en) | therapeutic rna for hpv positive cancer | |
PH12021551235A1 (en) | Elacestrant in combination with abemaciclib in women with breast cancer | |
AR095416A1 (en) | TREATMENT WITH CUTIRSEN THAT PRESENTS A REDUCED TOXICITY | |
AR122341A1 (en) | METHOD FOR THE TREATMENT OF CANCER USING ARTIFICIAL ADJUVANT CELL (AAVC) | |
AR111803A1 (en) | DERIVED FROM CICLOPENTAN [G] QUINAZOLIN-4-ONA AND ITS EMPLOYMENT IN THE TREATMENT OF CANCER RESISTANT TO PLATINUM | |
MX2022014231A (en) | ANTIBODY-DRUG CONJUGATES TARGETING uPARAP. | |
CL2018002438A1 (en) | Method and composition for the treatment of cancer or a skin lesion using a vaccine. | |
CL2021001623A1 (en) | Combination therapy with a raf inhibitor and a cdk4/6 inhibitor for use in treating cancer | |
MX2021001764A (en) | Combination therapy. |